Call for Artists: Design the Next HeartWorks Wine Label

Porter Family Vineyards is bottling a new vintage of HeartWorks Wine and we’re inviting artists from the CHD community to help bring it to life.

This label is more than a design. It’s a story. A perspective. A reflection of what it means to live with congenital heart disease.

If you or your child has CHD, this is your opportunity to share that story through art.

We are incredibly grateful for our long-time partners, Porter Family Vineyards. Through their generosity – donations, wine proceeds, and continued support – they have helped move this work forward in meaningful ways. This collaboration is one more way we bring the CHD community into everything we build.


Submission Details

Deadline: May 21
Who can submit: Artists impacted by CHD (children and adults)

Artwork requirements:

  • Must be portrait orientation (vertical)
  • Artist should sign their first name on the artwork
  • Please keep the original piece (winner will mail it to the vineyard)

What Happens Next

One artist will be selected to have their artwork featured on 600+ bottles of HeartWorks Wine, shared with supporters across the country.

All artists who submit will receive a small token of appreciation from HeartWorks as a thank you for sharing their creativity and story.


Why It Matters

Every bottle helps spark conversations, raise awareness, and support the future of congenital heart disease innovation.

This is your chance to be part of that story!

Purchase last year’s bottle here: https://porterfamilyvineyards.com/HeartWorksIV

Share the Post:

Related Posts

Microscope image of fibroblast production

From Skin Cells to Heart Cells: How HeartWorks Is Building Regenerative Therapies

HeartWorks was created to accelerate therapies for congenital heart disease by bringing research, manufacturing, and clinical care together under one mission.At HeartWorks, our regenerative medicine platform begins with something remarkably simple: a small skin biopsy.

Those cells are reprogrammed into stem cells, expanded in our manufacturing facility, and then transformed into bioengineered heart muscle cells – all using the patient’s own cells. The goal? To create therapies designed to strengthen hearts affected by congenital heart disease while minimizing the risk of immune rejection.

Read More

Send A Message

This field is for validation purposes and should be left unchanged.
Name(Required)
Please let us know what's on your mind. Have a question for us? Ask away.